



Advanced Diagnostic
Laboratories

Dear Valued Client;

This notification, dated Tuesday October 5, 2021, is to inform you that test code NTM10 (the susceptibility testing panel for slowly growing mycobacteria), has been discontinued and replaced with NTM15. This was a result of improvements to sensitivity testing and reporting for slowly growing mycobacteria. These improvements include an increase in the range in concentrations tested for amikacin, the reporting of minimum inhibitory concentrations and interpretive breakpoints for minocycline for *M. kansasii* and other non-MAC mycobacteria, and the transition of clofazimine testing to the broth microdilution method. Along with the test change, a marginal increase in cost went effective on May 17, 2021.

Drugs that are included in NTM15 include the following;
AMK (Amikacin), CIP (Ciprofloxacin), CLF (Clofazimine), CLR (Clarithromycin), DOX (Doxycycline), LZD (Linezolid), MIN (Minocycline), MXF (Moxifloxacin), RFB (Rifabutin), RIF (Rifampin), EMB (Ethambutol), RIF/EMB (Rifampin & Ethambutol Synergy), STR (Streptomycin), & TMP/SXT (Trimethoprim/Sulfamethoxazole).

Following this notification, all previous NTM10 testing will be automatically upgraded to NTM15 and no further action is needed.

If you have any questions, or need to discuss alternative options for sensitivity testing, please contact our Client Service Team at 800-550-6227 or ClinRefLabs@NJHealth.org.

Sincerely,

A handwritten signature in black ink, appearing to read "Reeti Khare".

Reeti Khare
Director, Mycobacteriology and Respiratory Infections Laboratory
Advanced Diagnostic Laboratories, National Jewish Health

njlabs.org | 800.550.6227 (toll-free) | 800.652.9556 (fax)

[Unsubscribe](#) from emails from this list.